ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2021
A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1.
Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes.British journal of cancer · 2026Article
- Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.Journal for immunotherapy of cancer · 2026Article
- Dosing, duration, and timing controversies in determining immune checkpoint inhibitor dosing regimens.NPJ precision oncology · 2026Article
- Article
- An Asymptotic Analysis of Bivalent Monoclonal Antibody-Antigen Binding.Bulletin of mathematical biology · 2025Article
- Understanding antibody-target antigen interactions and the avidity effect using mathematical modelling.Journal of the Royal Society, Interface · 2025Article
- Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.Journal for immunotherapy of cancer · 2022Article
- A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
Abstract
Receptor occupancy (RO) assessment by flow cytometry is an important pharmacodynamic (PD) biomarker in the clinical development of large molecules such as monoclonal therapeutic antibodies (mAbs). The total-drug-bound RO assay format directly assesses mAb binding to cell surface targets using anti-drug detection antibodies. Here, we generated a flow cytometry detection antibody specifically binding to mAbs of the IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.